

Christina L. Race, PA-C

Dawes Fretzin Clinical Research Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030
Fax (317) 516-5031
E-mail: christinadfcrg@gmail.com

Dawes Fretzin Dermatology Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Butler University (Indianapolis, IN)
Bachelor of Health Science/Physician Assistant, 2000

- Dean's List
- Graduated with Honors

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Sub-Investigator, 2004-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Physician Assistant, 2000-Present

Indiana Blood Center/Tissue Bank (Indianapolis, IN)
Donor Procurement, 1999-00

Methodist Hospital Emergency Department (Indianapolis, IN)
Emergency Room Technician, 1997-98

License/Certifications

Indiana State Physician Assistant License 10000471A
NCCAA 1045335
CPR/AED Certified
ACLS Certified
TB Certified
Adjunct Faculty Butler University
CITI GCP Certification

Professional Societies

Membership to the American Academy of Physician Assistants
Membership to the Society of Dermatology Physician Assistants
Membership to the Indiana Academy of Physician Assistants
House of Delegates Student Representative for Physician Assistant organization (Butler University)
Fundraising chair for Butler University Methodist Physician Assistant organization (Butler University)

*C. Race PA-C
17-JUN-2026*

Christina L. Race, PA-C

Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Johnson & Johnson	732-ACN-2035	Acne	Sub-I	4	01-Jun-07
Galderma	RD.06.SPR.18088	Acne	Sub-I	3	22-Jan-08
Novum	70608502	Acne	Sub-I	2	03-Sep-08
Stiefel	W0261-301	Acne	Sub-I	3	22-Oct-09
Stiefel	W0260-301	Acne	Sub-I	3	18-Jan-11
Dow Pharma	DPSI-IDP-107-P2-02	Acne	Sub-I	2	14-Jun-11
Cipher	ISOCT.08.01	Acne	Sub-I	3	18-Oct-11
Warner Chilcott	PR-10411	Acne	Sub-I	2	09-Jan-13
Taro	CLBG1210	Acne	Sub-I	3	04-Feb-14
Cipher	RAN.13.01	Acne	Sub-I	3	13-Mar-14
Allergan	225678-007	Acne	Sub-I	3	21-Jan-15
Valeant	V01-123A-501	Acne	Sub-I	1b	14-Mar-17
Foamix	FX2014-05	Acne	Sub-I	3	27-Apr-17
Valeant	V01-121A-302	Acne	Sub-I	3	09-May-17
Elorac	EL-1006-01-01	Acne	Sub-I	2	06-Jun-17
Ranbaxy	ABS1517LT	Acne	Sub-I	4	24-Apr-18
Dr. Reddy's	DFD-03-CD-006	Acne	Sub-I	2	31-Jul-18
Foamix	FX2017-22	Acne	Sub-I	2	28-Sep-18
Bausch Health	V01-121A-501	Acne	Sub-I	1b	01-Oct-19
Bausch Health	V01-121A-302	Acne	Sub-I	3	01-Mar-21
UPENN	Acne	Acne	Sub-I	4	16-Apr-25
Sanofi	VBE00001	Acne	Sub-I	1/2	24-Feb-26
Aczone	225678-007	Acne	Sub-I	3	01-Mar-16
3M Pharma	1502-IMIQ	Actinic Keratosis	Sub-I	3b	04-Aug-05
3M Pharma	1502-IMIQ	Actinic Keratosis	Sub-I	3b	04-Aug-05
3M Pharma	1502-IMIQ-13	Actinic Keratosis	Sub-I	3b	06-Jun-07
Peplin	PEP005-016	Actinic Keratosis	Sub-I	3b	07-Jan-10
Peplin	PEP005-028	Actinic Keratosis	Sub-I	3b	21-Jan-10
Peplin	PEP005-020	Actinic Keratosis	Sub-I	3b	26-Mar-10
Peplin	PEP005-030	Actinic Keratosis	Sub-I	3b	11-Jan-11
Peplin	PEP005-032	Actinic Keratosis	Sub-I	3b	11-Jan-11
Actavis	094-3153-301	Actinic Keratosis	Sub-I	4	11-Jun-14
LEO	LP0105-1012	Actinic Keratosis	Sub-I	1/2	13-Aug-14
LEO	LP0084-1148	Actinic Keratosis	Sub-I	2	15-Sep-15
Perrigo	PRG-NY-14-019	Actinic Keratosis	Sub-I	3	14-Dec-15
Actavis	094-8151-301	Actinic Keratosis	Sub-I	4	17-Dec-15
Actavis	094-8152-301	Actinic Keratosis	Sub-I	4	22-May-17
LEO	LP0105-1032	Actinic Keratosis	Sub-I	3	13-Oct-17
Athenex	KX01-AK-004	Actinic Keratosis	Sub-I	3	21-Nov-19
Merck	A-11107	Allergen Immunotherapy	Sub-I	OBS	09-Apr-13
Pfizer	B7931005	Alopecia Areata	Sub-I	2a	12-Mar-19
DRG Abacus	7785	Alopecia Areata	Sub-I	OBS	01-Sep-19

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Evidera	EVA-20417-00	Alopecia Areata	Sub-I	OBS	11-Mar-20
Pfizer	B7981015	Alopecia Areata	Sub-I	2b/3	03-Aug-21
Relstone	RSJ10521	Alopecia Areata	Sub-I	2	26-Aug-21
AnaptysBio	ANB030-201	Alopecia Areata	Sub-I	2	22-Mar-23
Horizon	HZNP-DAX-201	Alopecia Areata	Sub-I	2a	28-Mar-23
Concert	CP543.3001	Alopecia Areata	Sub-I	3	13-Jul-23
Arena	APD334-205	Alopecia Areata	Sub-I	2	30-Aug-23
Pfizer	B7981031	Alopecia Areata	Sub-I	1	17-Oct-23
Inmagene	IMG-007-002	Alopecia Areata	Sub-I	1b/2a	28-Jun-24
Pfizer	B7981032	Alopecia Areata	Sub-I	3	01-Aug-24
Aslan	ASLAN003-004	Alopecia Areata	Sub-I	2a	12-Aug-24
Sanofi	DRI18180	Alopecia Areata	Sub-I	2	10-Feb-25
Lilly	I4V-MC-JAIR	Alopecia Areata	Sub-I	3	13-Mar-25
Adelphi	AG9909	Alopecia Areata	Sub-I	OBS	15-Apr-26
Concert	CP543.5001	Alopecia Areata	Sub-I	3	28-Apr-26
DrenBio	DR-01-AIM-001	Alopecia Areata	Sub-I	1b	ONGOING
HCW Biologics	HCWALO101	Alopecia Areata	Sub-I	1b	ONGOING
Lilly	I4V-MC-JAIO	Alopecia Areata	Sub-I	3	ONGOING
Sun Pharma	CP543.3101	Alopecia Areata	Sub-I	3	ONGOING
Abbvie	M24-725	Alopecia Areata	Sub-I	3	ONGOING
CorEvitas	AA-565	Alopecia Areata	Sub-I	OBS	ONGOING
Pfizer	B7981027	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981028	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981094	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981110	Alopecia Areata	Sub-I	3	ONGOING
Pelage	PP405-2001	Androgenetic Alopecia	Sub-I	2a	24-Nov-25
Pelage	PP405-2002	Androgenetic Alopecia	Sub-I	2/3	ONGOING
Veradermics	250-13951-302	Androgenetic Alopecia	Sub-I	3	ONGOING
Veradermics	250-13951-306	Androgenetic Alopecia	Sub-I	3	ONGOING
GSK	SAS115358	Asthma	Sub-I	4	30-Oct-13
GSK	SAS115359	Asthma	Sub-I	4	01-May-14
GSK	201551	Atopic Dermatitis	Sub-I	3	07-Jul-05
Genentech	ACD3331g	Atopic Dermatitis	Sub-I	2	06-Oct-05
Ceragenix	CPI-2006-002	Atopic Dermatitis	Sub-I	2	23-Apr-07
Taro	TACR-0707	Atopic Dermatitis	Sub-I	2	12-May-09
Astellas	FHI-03-0-161/FG-506-06-37	Atopic Dermatitis	Sub-I	2	01-Oct-12
Anacor	AN2728-AD-203	Atopic Dermatitis	Sub-I	2a	21-Jan-13
Novartis	CBPR277X2101	Atopic Dermatitis	Sub-I	1	13-Feb-13
Anacor	AN2728-AD-302	Atopic Dermatitis	Sub-I	3	11-Aug-15
Anacor	AN2728-AD-303	Atopic Dermatitis	Sub-I	3	11-Nov-15
Regeneron	R668-AD-1314	Atopic Dermatitis	Sub-I	2	10-Dec-15
Regeneron	R668-AD-1334	Atopic Dermatitis	Sub-I	3	31-May-16
MedImmune	D5240C00001	Atopic Dermatitis	Sub-I	2a	22-Sep-16

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Chugai	CIM003JG	Atopic Dermatitis	Sub-I	2	20-Oct-16
Regeneron	R668-AD-1415	Atopic Dermatitis	Sub-I	3	08-Feb-17
GSK	203121	Atopic Dermatitis	Sub-I	2	29-Mar-17
Pfizer	B7451006	Atopic Dermatitis	Sub-I	2b	26-Apr-17
Regeneron	R668-AD-1225	Atopic Dermatitis	Sub-I	3	27-Sep-17
LEO	LP0156-1294	Atopic Dermatitis	Sub-I	OBS	24-Oct-17
GSK	205050	Atopic Dermatitis	Sub-I	2a	11-Jan-18
Sun Pharma	71542612	Atopic Dermatitis	Sub-I	3	15-Feb-18
Regeneron	R668-AD-1607	Atopic Dermatitis	Sub-I	1b	10-Apr-18
Incyte	INCB18424-206	Atopic Dermatitis	Sub-I	2	18-May-18
Novan	NI-AD101	Atopic Dermatitis	Sub-I	1b	25-Jun-18
Regeneron	R668-AD-1526	Atopic Dermatitis	Sub-I	3	19-Jul-18
Dermavant	RVT-502-2001	Atopic Dermatitis	Sub-I	2	01-Aug-18
Dermavant	RVT-501-2007	Atopic Dermatitis	Sub-I	1b	03-Aug-18
Pfizer	C0341001	Atopic Dermatitis	Sub-I	1	09-Oct-18
Lilly	I4V-MC-JAHL	Atopic Dermatitis	Sub-I	3	06-Dec-18
Pfizer	B7451012	Atopic Dermatitis	Sub-I	3	23-May-19
Pfizer	B7451013	Atopic Dermatitis	Sub-I	3	27-Jun-19
Dermira	DRM06-AD01	Atopic Dermatitis	Sub-I	2b	30-Jul-19
Kiniksa	KPL-716-C001	Atopic Dermatitis	Sub-I	1b	20-Sep-19
Asana	ASN002AD-201	Atopic Dermatitis	Sub-I	2b	25-Sep-19
LEO	LP0162-1326	Atopic Dermatitis	Sub-I	3	15-Oct-19
Galapagos	MOR106-CL-204	Atopic Dermatitis	Sub-I	2	28-Oct-19
Arcutis	ARQ-151-212	Atopic Dermatitis	Sub-I	2	10-Dec-19
Qurient	Q301-AD-P2-US002	Atopic Dermatitis	Sub-I	2	07-Jan-20
Ralexar	ALX-101-ATOP-204	Atopic Dermatitis	Sub-I	2	27-Jan-20
Asana	ASN002AD-201-EXT	Atopic Dermatitis	Sub-I	2	10-Mar-20
Pfizer	B7451036	Atopic Dermatitis	Sub-I	3	21-May-20
LEO	LP0133-1181	Atopic Dermatitis	Sub-I	1	25-Jun-20
Lilly	I4V-MC-JAIW	Atopic Dermatitis	Sub-I	3	03-Aug-20
Lilly	I4V-MC-JAIX	Atopic Dermatitis	Sub-I	3	03-Aug-20
Kyowa Hakko Kirin	4083-006	Atopic Dermatitis	Sub-I	2	15-Sep-20
Lilly	I4V-MC-JAHN	Atopic Dermatitis	Sub-I	3	21-Sep-20
Pfizer	B7451014	Atopic Dermatitis	Sub-I	3	19-Nov-20
Regeneron	R668-AD-1434	Atopic Dermatitis	Sub-I	3	09-Dec-20
Incyte	INCB18424-303	Atopic Dermatitis	Sub-I	3	28-Jan-21
Abbvie	M16-046	Atopic Dermatitis	Sub-I	3b	01-Feb-21
Xbiotech	2019-PT046	Atopic Dermatitis	Sub-I	2	21-Feb-21
Sanofi	LPS15496	Atopic Dermatitis	Sub-I	OBS	27-Apr-21
Sanofi	OBS15333	Atopic Dermatitis	Sub-I	OBS	27-Apr-21
Aclaris	ATI-1777-AD-201	Atopic Dermatitis	Sub-I	2a	23-Jun-21
Rapt	RPT193-01	Atopic Dermatitis	Sub-I	1	26-Jul-21
Pfizer	B7451050	Atopic Dermatitis	Sub-I	3b	12-Aug-21

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
BMX	BMX-DERM-01	Atopic Dermatitis	Sub-I	1/2	24-Aug-21
Pfizer	C3941002	Atopic Dermatitis	Sub-I	2a	15-Nov-21
Janssen	77474462ADM2003	Atopic Dermatitis	Sub-I	2a	06-Apr-22
Abbvie	M19-850	Atopic Dermatitis	Sub-I	3b	21-Apr-22
Janssen	77474462ADM2001	Atopic Dermatitis	Sub-I	3	16-May-22
Lilly	F1P-MC-KFAD	Atopic Dermatitis	Sub-I	1	21-Jun-22
BMS	IM011-005	Atopic Dermatitis	Sub-I	2	01-Aug-22
Dermira	DRM06-AD17	Atopic Dermatitis	Sub-I	3	24-Aug-22
BMS	IM018-005	Atopic Dermatitis	Sub-I	2	20-Sep-22
Celgene	CC-93538-AD-001	Atopic Dermatitis	Sub-I	2	07-Dec-22
Connect	CBP-201-WW004	Atopic Dermatitis	Sub-I	3	30-Dec-22
LEO	LP0162-1337	Atopic Dermatitis	Sub-I	3	27-Jan-23
Galderma	RD.06.SPR.118161	Atopic Dermatitis	Sub-I	3	13-Feb-23
GSK	215253	Atopic Dermatitis	Sub-I	1b	13-Jun-23
Arcutis	ARQ-151-313	Atopic Dermatitis	Sub-I	3	11-Jul-23
Pfizer	C3941005	Atopic Dermatitis	Sub-I	2b	01-Aug-23
OM1	DataDerm	Atopic Dermatitis	Sub-I	OBS	19-Aug-23
Evommune	EVO101-AD001	Atopic Dermatitis	Sub-I	2a	29-Aug-23
Alumis	ESK-001-006	Atopic Dermatitis	Sub-I	2	08-Sep-23
DermTech	20-03	Atopic Dermatitis	Sub-I	4	24-Oct-23
Acrotech	MEDI-MM36-301	Atopic Dermatitis	Sub-I	3	20-Nov-23
Evidera	EVA-25835	Atopic Dermatitis	Sub-I	OBS	15-Dec-23
Galderma	RD.06.SPR.118380	Atopic Dermatitis	Sub-I	2	21-Dec-23
Aslan	ASLAN004-003	Atopic Dermatitis	Sub-I	2b	04-Jan-24
Aclaris	ATI-1777-AD-202	Atopic Dermatitis	Sub-I	2b	06-Feb-24
Alumis	ESK-001-007	Atopic Dermatitis	Sub-I	2	13-Feb-24
TrialSpark	ASN008-201	Atopic Dermatitis	Sub-I	2	14-Feb-24
Cara	CR845-310501	Atopic Dermatitis	Sub-I	3	07-Mar-24
Kymab	KY1005-CT05	Atopic Dermatitis	Sub-I	2b	02-May-24
Rapt	RPT193-02	Atopic Dermatitis	Sub-I	2	07-Jun-24
Incyte	INCB18424-305	Atopic Dermatitis	Sub-I	3	26-Jun-24
Acrotech	MEDI-MM36-302	Atopic Dermatitis	Sub-I	3	16-Jul-24
Biosion	BSI-045B-002	Atopic Dermatitis	Sub-I	2a	18-Jul-24
Abbvie	M16-049	Atopic Dermatitis	Sub-I	2b	29-Oct-24
Abbvie	M23-696	Atopic Dermatitis	Sub-I	3b/4	29-Oct-24
Taro	RXLC-2118	Atopic Dermatitis	Sub-I	4	04-Dec-24
Incyte	INCB18424-902	Atopic Dermatitis	Sub-I	4	05-Feb-25
Pfizer	B7451015	Atopic Dermatitis	Sub-I	3	25-Mar-25
Lilly	J2T-MC-KGBO	Atopic Dermatitis	Sub-I	3b	01-Apr-25
Lilly	J2T-MC-KGBP	Atopic Dermatitis	Sub-I	3b	02-Apr-25
Dermira	DRM06-AD07	Atopic Dermatitis	Sub-I	3	09-Apr-25
Amgen	20210144	Atopic Dermatitis	Sub-I	3	29-Apr-25
Galderma	RD.06.SPR.118126	Atopic Dermatitis	Sub-I	2	11-Jun-25

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Abbvie	M24-601	Atopic Dermatitis	Sub-I	3b/4	12-Jun-25
LEO	LP0145-2240	Atopic Dermatitis	Sub-I	2b	25-Jun-25
Apollo	AP43CP03	Atopic Dermatitis	Sub-I	2	04-Nov-25
CastleBio Science	CBI_2021_ISD_DevVal_001	Atopic Dermatitis	Sub-I	4	02-Dec-25
Galderma	RD.06.SPR.118163	Atopic Dermatitis	Sub-I	3	20-Jan-26
Sanofi	EFC17561	Atopic Dermatitis	Sub-I	3	03-Feb-26
Abbvie	M16-045	Atopic Dermatitis	Sub-I	3	04-Feb-26
Amgen	20210145	Atopic Dermatitis	Sub-I	3	26-Feb-26
TARGET-DERM	TARGET-DERM	Atopic Dermatitis	Sub-I	4	06-Apr-26
Janssen	95475939ADM2001	Atopic Dermatitis	Sub-I	2b	12-May-26
Roche	CS45943	Atopic Dermatitis	Sub-I	2	N/A
Attovia	ATTO-3712-101	Atopic Dermatitis	Sub-I	1	ONGOING
Enveda	ENV-294-202	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-B002	Atopic Dermatitis	Sub-I	4	ONGOING
Organon	OG0505-3104	Atopic Dermatitis	Sub-I	3	ONGOING
Triveni Bio	TRIV-509-101	Atopic Dermatitis	Sub-I	2a	ONGOING
Triveni Bio	TRIV-573-101	Atopic Dermatitis	Sub-I	2	ONGOING
Abbvie	M16-047	Atopic Dermatitis	Sub-I	3	ONGOING
Abbvie	M17-380	Atopic Dermatitis	Sub-I	3	ONGOING
Aclaris	ATI-045-AD-201	Atopic Dermatitis	Sub-I	2b	ONGOING
Amgen	20210146	Atopic Dermatitis	Sub-I	3	ONGOING
Anacor	AN2728-AD-301-302-POST01	Atopic Dermatitis	Sub-I	OBS	ONGOING
Apogee	APG777-301	Atopic Dermatitis	Sub-I	3	ONGOING
Apollo	AP43CP04	Atopic Dermatitis	Sub-I	2b	ONGOING
CorEvitas	AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Corrona	Corrona-AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Galderma	SPR207806	Atopic Dermatitis	Sub-I	OBS	ONGOING
Janssen	95597528ADM2001	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-KGCE	Atopic Dermatitis	Sub-I	4	ONGOING
Pfizer	B7451023	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	B7451031	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	C4531002	Atopic Dermatitis	Sub-I	2	ONGOING
Pfizer	C4531005	Atopic Dermatitis	Sub-I	3	ONGOING
Roche	CS45570	Atopic Dermatitis	Sub-I	2	ONGOING
Sanofi	EFC17599	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	EFC17600	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	LTS17367	Atopic Dermatitis	Sub-I	2/3	ONGOING
Brickell	BBI-4000-CL-301	Axillary Hyperhidrosis	Sub-I	3	11-Aug-21
Genentech	THA3435g	Basal Cell Carcinoma	Sub-I	1	27-Jul-06
Akari	AK802	Bullous Pemphigoid	Sub-I	3	08-Sep-22
AstraZenaca	D325AC00002	Bullous Pemphigoid	Sub-I	3	31-Aug-23
Asana	ASN002AD-202	Chronic Hand Eczema	Sub-I	2	22-Jun-20
Arcutis	ARQ-252-205	Chronic Hand Eczema	Sub-I	1/2b	07-Aug-20

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Evimmune	EVO756-CIU001	Chronic Inducible Urticaria	Sub-I	2a	20-Jun-25
Celldex	CDX0159-07	Chronic Inducible Urticaria	Sub-I	2	25-Nov-25
Menlo	MTI-117	Chronic Pruritus of Unknown Origin	Sub-I	2	29-May-20
Sanofi	EFC16973	Chronic Pruritus of Unknown Origin	Sub-I	3	13-Nov-24
Novartis	CLOU064R12301	Chronic Pruritus of Unknown Origin	Sub-I	3	ONGOING
Galderma	SPR207913	Chronic Pruritus of Unknown Origin	Sub-I	2	ONGOING
Genentech	ACD4577g	Chronic Spontaneous Urticaria	Sub-I	2	10-Dec-09
Genentech	Q4882g	Chronic Spontaneous Urticaria	Sub-I	3	12-Sep-12
Novartis	CQGE031C2201	Chronic Spontaneous Urticaria	Sub-I	2b	29-Jun-16
Genentech	ML29510	Chronic Spontaneous Urticaria	Sub-I	4	27-Jun-17
Novartis	CQGE031C2302	Chronic Spontaneous Urticaria	Sub-I	3	30-Sep-22
Novartis	CQGE031C2302E1	Chronic Spontaneous Urticaria	Sub-I	3b	25-Oct-22
Celldex	CDX0159-02	Chronic Spontaneous Urticaria	Sub-I	1	10-Jan-23
Evidera	EVA-32391-01	Chronic Spontaneous Urticaria	Sub-I	OBS	13-Mar-23
Amgen	20190194	Chronic Spontaneous Urticaria	Sub-I	2b	20-Apr-23
Celldex	CDX0159-06	Chronic Spontaneous Urticaria	Sub-I	2	07-Nov-23
Escient	EP-262-201	Chronic Spontaneous Urticaria	Sub-I	2	26-Mar-25
InflaRX	INF904-P2.1	Chronic Spontaneous Urticaria	Sub-I	2a	04-Dec-25
Blueprint Medicines	BLU-808-1201	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Celldex	CDX0159-12	Chronic Spontaneous Urticaria	Sub-I	3	ONGOING
Celldex	CDX0159-17	Chronic Spontaneous Urticaria	Sub-I	3b	ONGOING
Jasper Therapeutics	JSP-CP-011	Chronic Spontaneous Urticaria	Sub-I	2a	ONGOING
Jasper Therapeutics	JSP-CP-014	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Novartis	CLOU064AUS04	Chronic Spontaneous Urticaria	Sub-I	OBS	ONGOING
Novartis	CQAB149B2346	COPD	Sub-I	3	16-Dec-08
Novartis	CQAB149B2335S	COPD	Sub-I	3	16-Jan-09
Forest	LAS-MD-38	COPD	Sub-I	3b	23-Nov-10
Novartis	CQAB149B2341	COPD	Sub-I	3	16-Dec-10
GSK	HZA106837	COPD	Sub-I	3a	22-Nov-11
Novartis	CQVA149A2336	COPD	Sub-I	3	07-May-14
GSK	CTT116855	COPD	Sub-I	3	16-Jun-15
GSK	LPL100601	Coronary Heart Disease	Sub-I	3	13-Aug-13
Celgene	CC-11050-CLE-002	Cutaneous Lupus Erythematosus	Sub-I	2	01-Dec-12
Pfizer	A6261008	Cutaneous Lupus Erythematosus	Sub-I	3	26-Feb-14
Janssen	NOCOMPOUNDLUN0001	Cutaneous Lupus Erythematosus	Sub-I	OBS	29-Oct-14
Biogen	230LE201	Cutaneous Lupus Erythematosus	Sub-I	2	22-Jul-20
Gilead	GS-US-497-5888	Cutaneous Lupus Erythematosus	Sub-I	1b	29-Nov-22
Biogen	230LE301	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Biogen	230LE305	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Merck	MS200569-0003	Cutaneous Lupus Erythematosus	Sub-I	2	16-Jan-25
Horizon	HZNP-DAX-202	Cutaneous Lupus Erythematosus	Sub-I	2	21-Nov-25
Merck	MS200569-0048	Cutaneous Lupus Erythematosus	Sub-I	1	28-Jan-26
Gilead	GS-US-497-6486	Cutaneous Lupus Erythematosus	Sub-I	2a	19-May-26

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Merck	MS504908_0008	Cutaneous Lupus Erythematosus	Sub-I	3	ONGOING
Ventus	VENT-03-201	Cutaneous Lupus Erythematosus	Sub-I	2a	ONGOING
Nflection	NFX-179-NFI-202	Cutaneous Neurofibroma	Sub-I	2	16-Oct-23
Regeneron	R2810-ONC-2251	Cutaneous Squamous Cell Carcinoma	Sub-I	3	28-May-26
CastleBio Science	CBI_2019_cSCC_PVS_001	Cutaneous Squamous Cell Carcinoma	Sub-I	4	ONGOING
Soligenix	HPN-CTCL-01	Cutaneous T-Cell Lymphoma	Sub-I	3	24-Feb-21
Elorac	EL-1007-01-01	Cutaneous T-Cell Lymphoma	Sub-I	3	20-Oct-22
Soligenix	HPN-CTCL-03-EUR	Cutaneous T-Cell Lymphoma	Sub-I	3	ONGOING
Lilly	F3Z-US-IOOV	Diabetes - Type 2	Sub-I	3	01-Oct-08
Merck	079-00	Diabetes - Type 2	Sub-I	3	01-Oct-08
Takeda	TAK-875_306	Diabetes - Type 2	Sub-I	3	26-Feb-14
Lilly	H6D-MC-LVGO	Erectile Dysfunciton	Sub-I	3	21-Mar-06
Lilly	I4K-MC-GPEC	Erectile Dysfunciton	Sub-I	2	25-Jan-12
Evidera	EVA-16679	Genital Psoriasis	Sub-I	OBS	01-Jun-15
Lilly	I1F-MC-RHBQ	Genital Psoriasis	Sub-I	3	17-May-18
Celgene	CC-10004-PSOR-025	Genital Psoriasis	Sub-I	3	27-Apr-22
AnaptysBio	ANB019-002	GPP	Sub-I	2a	20-Oct-20
AnaptysBio	ANB019-401	GPP/PPP	Sub-I	3	02-Mar-23
Regeneron	R668-AD-1924	Hand/Foot Dermatitis	Sub-I	3	22-Feb-23
Lilly	J2T-MC-KGCD	Hand/Foot Dermatitis	Sub-I	3b	ONGOING
Lilly	I4J-MC-HHBA	Healthy Volunteers - Biomarkers	Sub-I	N/A	01-Jun-10
Pfarming	C1 1205-01	Hereditary Angioedema	Sub-I	2	07-May-10
Inhibitex	INH-FV1-005	Herpes Zoster	Sub-I	2	10-Dec-10
CSL Bering	CSI324-2001	Hidradenitis Suppurativa	Sub-I	2	10-May-14
AstraZenaca	D5440C00001	Hidradenitis Suppurativa	Sub-I	2a	10-Dec-14
Novartis	CCJM112X2202	Hidradenitis Suppurativa	Sub-I	2	29-Mar-17
Abbvie	H13-147	Hidradenitis Suppurativa	Sub-I	OBS	25-Feb-20
Xbiotech	2019-PT047	Hidradenitis Suppurativa	Sub-I	2	21-Feb-21
ChemoCentryx	CL016_168	Hidradenitis Suppurativa	Sub-I	2	11-May-21
Pfizer	C2501007	Hidradenitis Suppurativa	Sub-I	2a	15-Feb-22
Abbvie	M20-040	Hidradenitis Suppurativa	Sub-I	2	15-Mar-22
Boehringer Ingelheim	1368-0052	Hidradenitis Suppurativa	Sub-I	2a	29-Mar-22
Novartis	CAIN457M2302	Hidradenitis Suppurativa	Sub-I	2/3	31-Oct-22
Boehringer Ingelheim	1368-0067	Hidradenitis Suppurativa	Sub-I	2	31-Jan-23
Janssen	77474462HDS2001	Hidradenitis Suppurativa	Sub-I	2	10-Feb-23
Moonlake	M1095-HS-201	Hidradenitis Suppurativa	Sub-I	2	02-Oct-23
Acelyrin	21102	Hidradenitis Suppurativa	Sub-I	2	16-Apr-24
Acelyrin	22107	Hidradenitis Suppurativa	Sub-I	3	26-Feb-25
Adelphi	AB6762B	Hidradenitis Suppurativa	Sub-I	OBS	01-Mar-25
Boehringer Ingelheim	1368-0098	Hidradenitis Suppurativa	Sub-I	2b/3	31-Jul-25
Novartis	CAIN457M2301E1	Hidradenitis Suppurativa	Sub-I	3	26-Aug-25
Incyte	INCB54707-302	Hidradenitis Suppurativa	Sub-I	3	23-Jan-26
Incyte	INCB54707-301	Hidradenitis Suppurativa	Sub-I	3	17-Feb-26

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Sanofi	ACT17841	Hidradenitis Suppurativa	Sub-I	2	19-Feb-26
Moonlake	M1095-HS-304	Hidradenitis Suppurativa	Sub-I	3	21-May-26
Incyte	INCB054707-801	Hidradenitis Suppurativa	Sub-I	3b	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-303	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Novartis	CCFZ533H12201BC	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Novartis	CLOU064J12301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Abbvie	M20-262	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Abbvie	M20-465	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Abbvie	M23-698	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Lilly	I7P-MC-DSAF	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Merck	MK7240-012	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Pfizer	B7981119	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Novartis	SPP100A-2409	Hypertension	Sub-I	2	21-Jun-10
Mayne	18-ICH-001	Lamellar Ichthyosis	Sub-I	2	17-Jan-22
Timber	TMB01-301/MUST	Lamellar Ichthyosis	Sub-I	3	03-Dec-24
Priovant	PVT-2201-304	Lichen Planopilaris	Sub-I	2/3	ONGOING
Incyte	INCB18424-216	Lichen Planus	Sub-I	2	25-Apr-24
Novartis	CGIA362C12201	Lichen Planus	Sub-I	2	ONGOING
Lilly	I5V-MC-TSAT	Low Testosterone	Sub-I	3	25-Jun-15
Evidera	EVA-36509-01	Lower Abdominal Fat	Sub-I	OBS	08-Nov-23
Evidera	EVA-36509-02	Lower Abdominal Fat	Sub-I	OBS	18-Jul-24
Evidera	EVA-36509-04	Lower Abdominal Fat	Sub-I	OBS	23-Jan-25
Evidera	EVA-36509-08	Lower Abdominal Fat	Sub-I	OBS	18-Sep-25
Evidera	146323-01	Lower Abdominal Fat	Sub-I	OBS	01-Nov-25
Evidera	152364-01	Lower Abdominal Fat	Sub-I	OBS	01-Jun-26
Novan	NI-MC201	Molluscum Contagiosum	Sub-I	2	09-Jan-19
Novan	NI-MC301	Molluscum Contagiosum	Sub-I	3	09-Jan-19
DermTech	17-06	Multi-Indication	Sub-I	4	17-Jun-24
Novartis	CFTY720DUS01	Multiple Sclerosis	Sub-I	4	25-Jul-12
Lilly	I1F-MC-B018	Nail Psoriasis	Sub-I	OBS	29-Jan-25
Quoin	CL-QRX003-001	Netherton Syndrome	Sub-I	2	08-Apr-26
BioCryst	BCX17725-101	Netherton Syndrome	Sub-I	1	ONGOING
Quoin	CL-QRX003-002	Netherton Syndrome	Sub-I	2	ONGOING
Quoin	CL-QRX003-004	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-005	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-006	Netherton Syndrome	Sub-I	3	ONGOING
DermTech	21-02	Normal Skin	Sub-I	4	29-Jan-24
Mindera	MND-24-MK-02	Normal Skin	Sub-I	1	30-Sep-25
Evidera	EVA-27657	Notalgia Parasthetica	Sub-I	OBS	18-Mar-21
Cara	CR845-210601	Notalgia Parasthetica	Sub-I	2	11-Aug-22

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Evidera	EVA-37056-00	Notalgia Parasthetica	Sub-I	OBS	24-Apr-24
Cara	CR845-310601	Notalgia Parasthetica	Sub-I	2-3	02-Jul-24
Clexio	CLE400-NP-201	Notalgia Parasthetica	Sub-I	2	24-Jan-25
Lilly	I1L-MC-GAEB	Obesity	Sub-I	2	16-Jul-10
Hisamitsu	HTU-520-US01	Onychomycosis	Sub-I	2	01-May-13
XOMA	X052160	Osteoarthritis of the Hand	Sub-I	2	10-Apr-14
XOMA	X052162	Osteoarthritis of the Hand	Sub-I	2	10-Apr-14
XOMA	X052161	Osteoarthritis of the Hand	Sub-I	2	01-Jun-15
Pfizer	A3191172	Osteoarthritis/Rheumatoid Arthritis	Sub-I	4	19-Sep-16
Novartis	CAIN457A2312	Palmoplantar Psoriasis	Sub-I	3b	03-Apr-17
Abbvie	M15-994	Palmoplantar Psoriasis	Sub-I	3b	17-Jul-23
BMS	IM011-1112	Palmoplantar Psoriasis	Sub-I	4	02-Jul-25
AnaptysBio	ANB019-003	Palmoplantar Pustulosis	Sub-I	2	09-Jun-21
Aristea	RIST4721-202	Palmoplantar Pustulosis	Sub-I	2	12-May-23
Galderma	RD.06.SPR.18171	Papulopustular Rosacea	Sub-I	3	11-Sep-13
Cutanea	CLS001-CO-PR-001.01	Papulopustular Rosacea	Sub-I	2	17-Apr-14
Azitra	CTAR-403	Papulopustular Rosacea	Sub-I	1b/2a	10-Jun-21
Dr. Reddy's	DFD-29-CD-004	Papulopustular Rosacea	Sub-I	3	24-Jul-23
Evidera	EVA-20259	Pediatric Psoriasis	Sub-I	OBS	01-Oct-18
Sanofi	EFC16459	Prurigo Nodularis	Sub-I	3	25-May-22
Galderma	RD.06.SPR.202699	Prurigo Nodularis	Sub-I	3	13-Jun-22
Galderma	RD.06.SPR.203065	Prurigo Nodularis	Sub-I	3	13-Jun-22
Incyte	INCB18424-110	Prurigo Nodularis	Sub-I	1	09-May-25
InnoCare	ICP-CL-00609	Prurigo Nodularis	Sub-I	2	ONGOING
Sanofi	OBS17721	Prurigo Nodularis	Sub-I	4	ONGOING
Galderma	SPR207807	Prurigo Nodularis	Sub-I	OBS	ONGOING
Genentech	ACD2600g	Psoriasis	Sub-I	3	12-Jun-03
Genentech	ACD2601g	Psoriasis	Sub-I	3	15-Jul-04
Amgen	20030190	Psoriasis	Sub-I	4	04-May-05
Amgen	20030190	Psoriasis	Sub-I	4	04-May-05
Centocor	C0379T04	Psoriasis	Sub-I	2	17-Jun-05
Centocor	C0168T45	Psoriasis	Sub-I	OBS	20-Jun-06
Abbott	M03-656	Psoriasis	Sub-I	3	18-Sep-06
Genentech	ACD3753g	Psoriasis	Sub-I	4	04-Jan-07
Astellas	04-0-206	Psoriasis	Sub-I	3	05-Apr-07
Abbott	M05-736	Psoriasis	Sub-I	2	07-Jul-08
Centocor	C0743T12	Psoriasis	Sub-I	3	26-Feb-09
Abbott	M10-114	Psoriasis	Sub-I	3	15-Apr-09
Genzyme	HECTPS02507	Psoriasis	Sub-I	2	13-May-09
Abbott	M10-238	Psoriasis	Sub-I	3	09-Jul-09
Abbott	M06-890	Psoriasis	Sub-I	3	29-Jul-09
Genentech	ACD4412n	Psoriasis	Sub-I	4	20-Sep-09
Genentech	ACD3101g	Psoriasis	Sub-I	3b	07-Oct-09

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Genentech	ACD3101g	Psoriasis	Sub-I	3b	07-Oct-09
Abbott	M03-658	Psoriasis	Sub-I	3	15-Oct-09
Celgene	CC-10004-PSOR-005	Psoriasis	Sub-I	2b	26-Jan-10
Lilly	I1F-MC-RHAG	Psoriasis	Sub-I	2	02-Jun-10
Lilly	I1X-MC-BDAD	Psoriasis	Sub-I	2	30-Jul-10
Celgene	CC-10004-PSOR-005E	Psoriasis	Sub-I	2b	11-Aug-10
Wyeth	3199K2-1105-US	Psoriasis	Sub-I	1	06-Dec-10
Novo-Nordisk	NN8226-1848	Psoriasis	Sub-I	1/2a	03-Mar-11
Amgen	20070559	Psoriasis	Sub-I	3	15-Mar-11
Centocor	C0743T08	Psoriasis	Sub-I	3	27-Jul-11
Wyeth	3226K1-1002-WW	Psoriasis	Sub-I	1	19-Sep-11
Centocor	C0743T09	Psoriasis	Sub-I	3	16-Dec-11
Abbott	M10-016	Psoriasis	Sub-I	3	06-Mar-12
Maruho	M518101-US01	Psoriasis	Sub-I	2b	07-Mar-12
Schering Plough	PO5495	Psoriasis	Sub-I	2	30-Jan-13
Amgen	20040210	Psoriasis	Sub-I	OBS	19-Feb-13
Amgen	20040210	Psoriasis	Sub-I	OBS	19-Feb-13
Lilly	I1F-MC-RHBL	Psoriasis	Sub-I	3	03-Oct-13
Janssen	CNT01959PSO2001	Psoriasis	Sub-I	2	01-Nov-13
GSK	200851	Psoriasis	Sub-I	3	01-Dec-13
Pfizer	A3921078	Psoriasis	Sub-I	3	06-Jan-14
Amgen	HRA1889A	Psoriasis	Sub-I	OBS	20-Aug-14
Novartis	CAIN457A2223	Psoriasis	Sub-I	2	08-May-15
Celgene	CC-10004-PSOR-010	Psoriasis	Sub-I	3b	15-Jul-15
Pfizer	B7451005	Psoriasis	Sub-I	2	02-Sep-15
Maruho	M518101-US02	Psoriasis	Sub-I	3	11-Sep-15
Amgen	20120104	Psoriasis	Sub-I	3	22-Dec-15
Janssen	38515168PSO2001	Psoriasis	Sub-I	2	13-Jan-16
Novartis	CCJM112X2101	Psoriasis	Sub-I	1	26-Jan-16
Amgen	HRA1603A (20130126)	Psoriasis	Sub-I	OBS	11-Feb-16
Galderma	RD.06.SPR.18104	Psoriasis	Sub-I	4	25-Feb-16
Amgen	20101177	Psoriasis	Sub-I	4	18-Mar-16
Evidera	EVA-18225	Psoriasis	Sub-I	OBS	02-Jun-16
Tolmar	TOL2707A	Psoriasis	Sub-I	3	02-Jun-16
Janssen	CNT01959PSO3003	Psoriasis	Sub-I	3	19-Jul-16
Sandoz	GP17-301	Psoriasis	Sub-I	3	24-Jul-16
Evidera	EVA-18225-01	Psoriasis	Sub-I	OBS	03-Aug-16
Promius	DFD06-CD-005	Psoriasis	Sub-I	3	29-Aug-16
Celgene	CC-10004-PSOR-008	Psoriasis	Sub-I	3	06-Oct-16
Pfizer	A3921061	Psoriasis	Sub-I	3	11-Oct-16
Novartis	CAIN457A2317	Psoriasis	Sub-I	3b	19-Nov-16
Novartis	CAIN457A2313	Psoriasis	Sub-I	3b	04-Apr-17
Novartis	CAIN457A2303	Psoriasis	Sub-I	3	04-Apr-17

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Amgen	20120363	Psoriasis	Sub-I	OBS	12-Apr-17
Lilly	I1F-MC-RHBP	Psoriasis	Sub-I	3	07-Jun-17
UCB	PS0010	Psoriasis	Sub-I	2b	12-Jun-17
BMS	IM011-011	Psoriasis	Sub-I	2	23-Aug-17
Stiefel	STF115750	Psoriasis	Sub-I	1	30-Aug-17
Janssen	CNT01275PSO3013	Psoriasis	Sub-I	3	05-Oct-17
Baxalta	911401	Psoriasis	Sub-I	3	24-Oct-17
Novartis	CAIN457A2304	Psoriasis	Sub-I	3	25-Oct-17
Novartis	CAIN457A2304E1	Psoriasis	Sub-I	3	25-Oct-17
Novartis	CAIN457A2302E1	Psoriasis	Sub-I	3	18-Nov-17
Boehringer Ingelheim	1311.28	Psoriasis	Sub-I	3	21-Nov-17
Sun Pharmaceuticals	71542611	Psoriasis	Sub-I	3	16-Feb-18
UCB	PS0003	Psoriasis	Sub-I	3	01-Apr-18
Pfizer	B7931004	Psoriasis	Sub-I	2a	08-May-18
Pfizer	B7931004	Psoriasis	Sub-I	2a	08-May-18
Allergan	1957-201-001	Psoriasis	Sub-I	2b	22-May-18
Galderma	RD.06.SPR.18131	Psoriasis	Sub-I	4	29-Aug-18
Novartis	CAIN457A2326	Psoriasis	Sub-I	3	26-Sep-18
Janssen	CNT01959PSO3009	Psoriasis	Sub-I	3	30-Oct-18
Novartis	CAIN457A2310	Psoriasis	Sub-I	3	31-Oct-18
Boehringer Ingelheim	1297.9	Psoriasis	Sub-I	3	01-Jan-19
Lilly	I1F-MC-RHAZ	Psoriasis	Sub-I	3	23-Jan-19
Sienna	SNA-120-202	Psoriasis	Sub-I	2	01-Feb-19
Dermira	PS0003	Psoriasis	Sub-I	3	13-Mar-19
Dr. Reddy's	PPC-06-CD-004	Psoriasis	Sub-I	2	28-May-19
Novartis	CAIN457AUS07	Psoriasis	Sub-I	4	03-Jun-19
Lilly	I7P-MC-DSAB	Psoriasis	Sub-I	1	29-Aug-19
Lilly	I7P-MC-DSAB	Psoriasis	Sub-I	1	29-Aug-19
Kadmon	KD025-211	Psoriasis	Sub-I	2	07-Nov-19
Lilly	I1F-MC-RHBC	Psoriasis	Sub-I	3	17-Dec-19
Merck	MK3222-010	Psoriasis	Sub-I	3	28-Jan-20
Akros	AE451-G-18-004	Psoriasis	Sub-I	2/3	12-May-20
Dermavant	DMVT-505-3001	Psoriasis	Sub-I	3	22-Jul-20
Lilly	I6T-MC-AMAJ	Psoriasis	Sub-I	3	22-Jul-20
Lilly	I1F-MC-RHCR	Psoriasis	Sub-I	4	23-Jul-20
Janssen	CNT01959PSO3002	Psoriasis	Sub-I	3	10-Sep-20
Celgene	CC-10004-PSOR-022	Psoriasis	Sub-I	3	22-Oct-20
Novartis	CAIN457A2324	Psoriasis	Sub-I	3b	10-Nov-20
Arcutis	ARQ-154-204	Psoriasis	Sub-I	2b	02-Dec-20
BMS	IM011-047	Psoriasis	Sub-I	3	19-Jan-21
Arcutis	ARQ-151-302	Psoriasis	Sub-I	3	31-Mar-21
Arcutis	ARQ-151-306	Psoriasis	Sub-I	3	28-Apr-21
GSK	200853	Psoriasis	Sub-I	3	01-May-21

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Dermavant	DMVT-505-3003	Psoriasis	Sub-I	2/3	08-Jun-21
Boehringer Ingelheim	1407-0030	Psoriasis	Sub-I	2	22-Jul-21
Lilly	I6T-MC-AMBK	Psoriasis	Sub-I	2/3	28-Jul-21
Boehringer Ingelheim	1407-0005	Psoriasis	Sub-I	2	21-Oct-21
Lilly	F1P-MC-KFAC	Psoriasis	Sub-I	1	03-Nov-21
Lilly	I6T-MC-AMAH	Psoriasis	Sub-I	3	28-Apr-22
Amgen	20190232	Psoriasis	Sub-I	3	08-Sep-22
Janssen	77242113PSO2001	Psoriasis	Sub-I	2b	28-Sep-22
Abbvie	M19-164	Psoriasis	Sub-I	3b	29-Sep-22
Abbvie	M19-164 Companion	Psoriasis	Sub-I	3b	29-Sep-22
Aurigene	AUR101-202	Psoriasis	Sub-I	2	12-Oct-22
Arcutis	ARQ-151-311	Psoriasis	Sub-I	3	08-Nov-22
Nimbus	4858-201	Psoriasis	Sub-I	2b	05-Dec-22
Biocon	BIO-USTEKI-305	Psoriasis	Sub-I	3	20-Dec-22
Janssen	77242113PSO2002	Psoriasis	Sub-I	2b	23-Jan-23
Abbvie	M15-997	Psoriasis	Sub-I	3	20-Mar-23
Abbvie	M18-816	Psoriasis	Sub-I	2	20-Mar-23
Abbott	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
Abbott	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
PSOLAR	C0168Z03	Psoriasis	Sub-I	OBS	18-May-23
Abbvie	M20-326	Psoriasis	Sub-I	4	17-Jul-23
Celgene	CC-10004-PPSO-003	Psoriasis	Sub-I	3	03-Aug-23
Biocon	BM12H-PSO-03-G-02	Psoriasis	Sub-I	3	11-Jan-24
Ventyx	VTX958-201	Psoriasis	Sub-I	2	13-Feb-24
Janssen	77242113PSO3001	Psoriasis	Sub-I	3	19-Mar-24
DICE Therapeutics	DCE806201	Psoriasis	Sub-I	2	28-Mar-24
Mindera	MND-21-MKPs-02	Psoriasis	Sub-I	4	28-May-24
LITE	PCS-1608-35830	Psoriasis	Sub-I	2/3	05-Jul-24
UCB	PS0020	Psoriasis	Sub-I	2	17-Jul-24
Sanofi	DRI17849	Psoriasis	Sub-I	2	03-Dec-24
Janssen	77242113PSO3003	Psoriasis	Sub-I	3	14-Jan-25
Janssen	77242113PSO3002	Psoriasis	Sub-I	3	20-Feb-25
BMS	IM011-075	Psoriasis	Sub-I	3b	06-May-25
Janssen	CNT01959PSO3018	Psoriasis	Sub-I	3b	10-Sep-25
Takeda	TAK279-3001	Psoriasis	Sub-I	3	20-Jan-26
Alumis	ESK-001-016	Psoriasis	Sub-I	3	17-Feb-26
Dermavant	DMVT-505-3004	Psoriasis	Sub-I	3	11-Mar-26
Celgene	CC-10004-PPSO-004	Psoriasis	Sub-I	3b	24-Mar-26
Takeda	TAK-279-PsO-3004	Psoriasis	Sub-I	3	02-Jun-26
Abbvie	M24-541	Psoriasis	Sub-I	4	02-Jun-26
Alumis	ESK-001-018	Psoriasis	Sub-I	3	ONGOING
InventisBio	D2570-207	Psoriasis	Sub-I	2	ONGOING
Takeda	TAK279-3003	Psoriasis	Sub-I	3	ONGOING

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Amgen	20200196	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1128	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1130	Psoriasis	Sub-I	3b/4	ONGOING
CorEvitas	CorEvitas-PSO-505	Psoriasis	Sub-I	OBS	ONGOING
Corrona	Corrona-PSO-550	Psoriasis	Sub-I	4	ONGOING
Lilly	I1F-MC-RHDC	Psoriasis	Sub-I	3b	ONGOING
Lilly	I1F-MC-RHDD	Psoriasis	Sub-I	3b	ONGOING
UCB	PS0021	Psoriasis	Sub-I	3	ONGOING
UPENN	CP3	Psoriasis	Sub-I	4	ONGOING
AbGenomics	2012.005.01	Psoriasis	Sub-I	2a	15-Apr-14
AbGenomics	2014.002.01	Psoriasis	Sub-I	2	09-Apr-15
Abcentra	ORT-2020-01	Psoriasis	Sub-I	2	21-Feb-23
Amgen	20030106	Psoriatic Arthritis	Sub-I	3	09-Nov-04
Celgene	CC-10004-PSA-004	Psoriatic Arthritis	Sub-I	3	14-Dec-12
Janssen	CNT01275PSA3002	Psoriatic Arthritis	Sub-I	3	17-Jan-13
Janssen	CNT01275PSA3001	Psoriatic Arthritis	Sub-I	3	06-Aug-13
Janssen	CNT0148PSA3001	Psoriatic Arthritis	Sub-I	3	08-Sep-15
Janssen	CNT01959PSA2001	Psoriatic Arthritis	Sub-I	2a	01-Mar-17
Abbvie	H15-457	Psoriatic Arthritis	Sub-I	OBS	25-Oct-17
Janssen	CNT01959PSA3001	Psoriatic Arthritis	Sub-I	3	10-Jul-18
Janssen	CNT01959PSA3002	Psoriatic Arthritis	Sub-I	3	10-Jul-18
Novartis	CAIN457F2318	Psoriatic Arthritis	Sub-I	3	06-Sep-18
Novartis	CAIN457P12302	Psoriatic Arthritis	Sub-I	3	12-Sep-22
Nimbus	4858-202	Psoriatic Arthritis	Sub-I	2b	29-Mar-23
Novartis	CAIN457A02001B	Psoriatic Arthritis	Sub-I	4	23-Jan-25
Boehringer Ingelheim	1368-0140	Pyoderma Gangrenosum	Sub-I	3	ONGOING
Merck	MK-0663-107	Rheumatoid Arthritis	Sub-I	3	29-Jul-14
Perrigo	PRG-NY-14-022	Rosacea	Sub-I	3	17-Nov-15
Cutanea	CLS001-CO-PR-006	Rosacea	Sub-I	3	07-Mar-18
Galderma	GLI.04.SPR.US10120	Rosacea	Sub-I	4	01-Nov-09
Evidera	EVA-20371-01	Scalp Psoriasis	Sub-I	OBS	11-Jan-24
BMS	IM011-220	Scalp Psoriasis	Sub-I	3b/4	19-Nov-24
Arcutis	ARQ-154-304	Seborrheic Dermatitis	Sub-I	3	06-Jul-22
Lilly	F1K-US-EVDO	Sepsis	Sub-I	4	01-Oct-09
Evidera	EVA-44850	Skin Tone Assessment	Sub-I	OBS	ONGOING
Merck	009-00	Vaccine	Sub-I	2	26-Feb-13
RXI	RXI-SCP-1502	Verruca Vulgaris	Sub-I	2a	06-Sep-18
Incyte	INCB18424-211	Vitiligo	Sub-I	2	28-Aug-20
DRG Abacus	8493	Vitiligo	Sub-I	OBS	01-Dec-20
Evidera	EVA-31203-01	Vitiligo	Sub-I	OBS	31-Oct-22
Abbvie	M19-051	Vitiligo	Sub-I	2	09-Nov-23
Merck	MK-6194-007	Vitiligo	Sub-I	2a	20-May-25
VYNE	VY2024-02	Vitiligo	Sub-I	2b	30-Jul-25

Christina L. Race, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Pfizer	B7981080	Vitiligo	Sub-I	3	10-Sep-25
Pfizer	B7981040	Vitiligo	Sub-I	3	05-Mar-26
Novartis	CGIA362B12201	Vitiligo	Sub-I	2	ONGOING
Abbvie	M19-044	Vitiligo	Sub-I	3	ONGOING
Abbvie	M25-264	Vitiligo	Sub-I	3	ONGOING
Lilly	J5D-MC-FPAD	Vitiligo	Sub-I	2	ONGOING
Pfizer	B7981041	Vitiligo	Sub-I	3	ONGOING
Aclaris	A-101-WART-202	Warts	Sub-I	2	11-Apr-18
Cutanea	CLS006-CO-PR-002	Warts	Sub-I	3	22-Jan-19
Aclaris	A-101-WART-301	Warts	Sub-I	3	26-Nov-19
Aclaris	A-101-WART-303	Warts	Sub-I	3	29-Jan-20